Literature DB >> 23010958

Symptom clusters and symptom interference of HCC patients undergoing TACE: a cross-sectional study in China.

Wenting Cao1, Juan Li, Chen Hu, Jie Shen, Xiangyan Liu, Yan Xu, Zhixia Ye.   

Abstract

OBJECTIVE: The aim of this study was to investigate the symptom and symptom clusters of patients with hepatocellular carcinoma (HCC) before and after transcatheter arterial chemoembolization (TACE), and to discuss the relationship between symptoms, symptom clusters, and symptom interference.
MATERIALS AND METHODS: Patients with HCC who received TACE were asked to rate their symptoms using the M. D. Anderson Symptom Inventory and the symptom checklist particularly for HCC. To determine the interrelationships among symptoms and identify the symptom clusters, a principal component analysis with varimax rotation was carried out on the symptom items. Spearman correlation analysis was done to assess the relationship between symptom clusters and symptom interference.
RESULTS: A total of 155 patients finished the whole procedure between November 2010 and May 2011. Before TACE, the five most severe symptoms, ranked in order, were fatigue (3.40 ± 2.26), distress (3.35 ± 2.60), sadness (3.01 ± 2.66), sleep disturbance (2.63 ± 2.57), and lack of appetite (2.26 ± 2.38). After TACE, fatigue (4.88 ± 2.31) was the most serious symptom, followed by sleep disturbance (4.80 ± 2.25), distress (4.59 ± 2.32), sadness (4.45 ± 2.16), lack of appetite (4.25 ± 2.51). Two symptom clusters were found before TACE: psychological symptom cluster and sickness symptom cluster. Two new symptom clusters were found after TACE: upper gastrointestinal symptom cluster and liver function impairment symptom cluster, with the two original symptom clusters remained relatively stable. The highest symptom interference items pre- and post-TACE were work and enjoyment of life, followed by mood. The symptoms of distress, sadness, fatigue, sleep disturbance, and lack of appetite were all significantly associated with the total interference (r = 0.443-0.615, p < 0.01 or p < 0.05). Symptom clusters were significantly correlated with the total symptom interference before and after TACE (r = 0.176-0.638, p < 0.01 or p < 0.05).
CONCLUSION: Psychological symptom cluster and sickness symptom cluster are common for HCC patients before and after TACE. Liver function impairment and upper gastrointestinal symptom clusters are directly related to TACE treatment. Both the symptoms and symptom clusters have significant interference on the daily life of HCC patients undergoing TACE. However, more work is needed to further clarify the symptom clusters associated with TACE and to test the effectiveness of TACE in easing symptoms and improving quality of life of HCC patients.

Entities:  

Mesh:

Year:  2012        PMID: 23010958     DOI: 10.1007/s00520-012-1541-5

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  21 in total

Review 1.  Prognostic prediction and treatment strategy in hepatocellular carcinoma.

Authors:  Jordi Bruix; Josep M Llovet
Journal:  Hepatology       Date:  2002-03       Impact factor: 17.425

2.  Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver.

Authors:  J Bruix; M Sherman; J M Llovet; M Beaugrand; R Lencioni; A K Burroughs; E Christensen; L Pagliaro; M Colombo; J Rodés
Journal:  J Hepatol       Date:  2001-09       Impact factor: 25.083

3.  Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults.

Authors:  S D Ryder
Journal:  Gut       Date:  2003-05       Impact factor: 23.059

4.  Comparison of transcatheter arterial chemoembolization and microsphere embolization for treatment of unresectable hepatocellular carcinoma: a meta-analysis.

Authors:  Feng Xie; Jiajie Zang; Xiaojing Guo; Feng Xu; Rongxi Shen; Long Yan; Jiamei Yang; Jia He
Journal:  J Cancer Res Clin Oncol       Date:  2011-12-18       Impact factor: 4.553

Review 5.  Current strategy for staging and treatment: the BCLC update and future prospects.

Authors:  Alejandro Forner; María E Reig; Carlos Rodriguez de Lope; Jordi Bruix
Journal:  Semin Liver Dis       Date:  2010-02-19       Impact factor: 6.115

Review 6.  Symptom clusters: concept analysis and clinical implications for cancer nursing.

Authors:  Hee-Ju Kim; Deborah B McGuire; Lorraine Tulman; Andrea M Barsevick
Journal:  Cancer Nurs       Date:  2005 Jul-Aug       Impact factor: 2.592

7.  Treatment-related symptom clusters in breast cancer: a secondary analysis.

Authors:  Hee-Ju Kim; Andrea M Barsevick; Lorraine Tulman; Paul A McDermott
Journal:  J Pain Symptom Manage       Date:  2008-08-20       Impact factor: 3.612

8.  Prognosis of hepatocellular carcinoma: the BCLC staging classification.

Authors:  J M Llovet; C Brú; J Bruix
Journal:  Semin Liver Dis       Date:  1999       Impact factor: 6.115

9.  Changing international trends in mortality rates for liver, biliary and pancreatic tumours.

Authors:  Shahid A Khan; Simon D Taylor-Robinson; Mireille B Toledano; Angus Beck; Paul Elliott; Howard C Thomas
Journal:  J Hepatol       Date:  2002-12       Impact factor: 25.083

10.  Assessment of patient-reported clinical outcome in pancreatic and other hepatobiliary cancers: the FACT Hepatobiliary Symptom Index.

Authors:  Susan Yount; David Cella; Kimberly Webster; Nancy Heffernan; Chih Chang; Linda Odom; Renilt van Gool
Journal:  J Pain Symptom Manage       Date:  2002-07       Impact factor: 3.612

View more
  11 in total

1.  Macro- and micro-environmental factors in clinical hepatocellular cancer.

Authors:  Petr Pancoska; Brian I Carr
Journal:  Semin Oncol       Date:  2014-03-07       Impact factor: 4.929

2.  Pharmacokinetic herb-drug interactions between Aidi injection and doxorubicin in rats with diethylnitrosamine-induced hepatocellular carcinoma.

Authors:  Yuan Lu; Jie Pan; Xiaoqing Zhu; Shuai Zhang; Chunhua Liu; Jia Sun; Yueting Li; Siying Chen; Jing Huang; Chuang Cao; Yonglin Wang; Yongjun Li; Ting Liu
Journal:  BMC Pharmacol Toxicol       Date:  2021-09-06       Impact factor: 2.483

3.  Impact of discriminant factors on the comfort-care of nurses caring for trans-arterial chemoembolisation patients.

Authors:  Myoung Soo Kim; Ju-Yeon Uhm
Journal:  Support Care Cancer       Date:  2022-06-16       Impact factor: 3.359

4.  lncRNA PCBP1-AS1 Aggravates the Progression of Hepatocellular Carcinoma via Regulating PCBP1/PRL-3/AKT Pathway.

Authors:  Tianping Luo; Yuan Gao; Guangyan Zhangyuan; Xiaoliang Xu; Cailin Xue; Lei Jin; Wenjie Zhang; Chunfu Zhu; Beicheng Sun; Xihu Qin
Journal:  Cancer Manag Res       Date:  2020-07-06       Impact factor: 3.989

5.  Symptom Interference Severity and Health-Related Quality of Life in Pulmonary Arterial Hypertension.

Authors:  Lea Ann Matura; Annette McDonough; Diane L Carroll
Journal:  J Pain Symptom Manage       Date:  2015-08-20       Impact factor: 3.612

6.  Safety and efficacy of a peripheral intravenous bolus of Licartin for the treatment of advanced hepatocellular carcinoma.

Authors:  Dong Dai; Wengui Xu; Jianjing Liu; Lei Zhu; Xiang Zhu; Xiaoying Ma
Journal:  Exp Ther Med       Date:  2013-09-30       Impact factor: 2.447

7.  Effects of acupressure on fatigue and depression in hepatocellular carcinoma patients treated with transcatheter arterial chemoembolization: a quasi-experimental study.

Authors:  Su-Chen Lan; Yueh-E Lin; Shu-Ching Chen; Yu-Fang Lin; Yu-Jen Wang
Journal:  Evid Based Complement Alternat Med       Date:  2015-02-23       Impact factor: 2.629

8.  Apatinib Inhibits the Invasion and Metastasis of Liver Cancer Cells by Downregulating MMP-Related Proteins via Regulation of the NF-κB Signaling Pathway.

Authors:  Xiaoxiao He; Zaozao Huang; Ping Liu; Qiuting Li; Mengmeng Wang; Mengjun Qiu; Zhifan Xiong; Shengli Yang
Journal:  Biomed Res Int       Date:  2020-06-19       Impact factor: 3.411

9.  Long non-coding RNA Myd88 promotes growth and metastasis in hepatocellular carcinoma via regulating Myd88 expression through H3K27 modification.

Authors:  Xiaoliang Xu; Yin Yin; Junwei Tang; Yu Xie; Zhuo Han; Xudong Zhang; Qiaoyu Liu; Xihu Qin; Xinli Huang; Beicheng Sun
Journal:  Cell Death Dis       Date:  2017-10-12       Impact factor: 8.469

Review 10.  Systematic Review of Studies Assessing the Health-Related Quality of Life of Hepatocellular Carcinoma Patients from 2009 to 2018.

Authors:  Danbee Kang; Sungkeun Shim; Juhee Cho; Hyo Keun Lim
Journal:  Korean J Radiol       Date:  2020-06       Impact factor: 3.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.